Recombinant VEGF (Bevacizumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all VEGF (Bevacizumab Biosimilar) products
- VEGF (Bevacizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
- 特异性
- The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.
- 产品特性
- Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.
- 亚型
- IgG1 kappa
-
anti-VEGF (Bevacizumab Biosimilar) antibody
Research Grade 适用: 人 ELISA 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- VEGF (Bevacizumab Biosimilar)
- Abstract
- VEGF (Bevacizumab Biosimilar) 产品
- 别名
- MVCD1 antibody, VEGF antibody, VPF antibody, vascular endothelial growth factor A antibody, VEGFA antibody
- 物质类
- Biosimilar
- 背景
-
Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
-
You are here:
